摘要
目的探索乙型肝炎病毒(HBV)基因型与拉米夫定、α-2b干扰素序贯治疗及单独予拉米夫定、α-2b干扰素治疗HBeAg阳性慢性乙型肝炎患者的疗效的相关性。方法HBeAg阳性慢乙肝患者,来自北京等四城市。分别拉米夫定、干扰素序贯治疗48周、拉米夫定48周或干扰素24周。停药后随访24周。评价HBV基因型与抗病毒治疗应答的关系。PCR-RFLP方法检测HBV基因型、基因亚型。结果225例患者中C基因型184例,其中C2亚型165例;B基因型41例,均为Ba亚型。治疗结束、随访结束时,各治疗组B型与C型间病毒学应答、血清学应答及完全应答率差异均无显著性。结论该四城市HBeAg阳性慢乙肝患者HBV基因型以B型和C型为主,亚型以Ba和C2亚型为主。治疗结束、随访结束时,各治疗组B型与C型间疗效无差异。
Objective To study the relationship of hepatitis B virus （HBV） genotypes and the response to antiviral therapy of HBeAg - positive chronic hepatitis B （CHB） patients. Methods 225 CHB patients from four cities were treated by three ways, sequential therapy with lamivudine and interferon ct -2b （IFN） for 48 weeks, lamivudine monothempy for 48 weeks or IFN for 24 weeks. The relationship between HBV genotypes and antiviral responses was investigated. PCR - RFLP was used to typing HBV genotypes and subgenotypes. Results All patients had single genotype, B or C. Every patient with genotype B belonged to subgroup Ba. Genotype C2 was the predominant subgroup in genotypo C. There was no significant difference between genotype B and C in antiviral responses in each group at the end of therapy and follow - up. Conclusion Genotypes B and C, subgroups Ba and C2 were predominant in HBeAg - positive CHB patients in these four cities. The antiviral efficacy between genotype B and C in each group had no difference.
出处
《临床肝胆病杂志》
CAS
2008年第3期169-171,共3页
Journal of Clinical Hepatology
基金
北京市科委病毒性肝炎重大项目(H020920020690)
北京大学211工程循证医学课题(91000-246156054)
